Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Feb;3(2):141–151. doi: 10.1177/1947601912457025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2012

PMC Copyright notice

Figure 1. — Survival curves of mice treated with the indicated agents. Median survivals of A549-injected mice (days): control (C), 9.0; cisplatin, 12.5; MRK-003 (GSI), 15.5; GSI+cisplatin, 19.5; GSI+MK-0646, 26.0; erlotinib, 16.0; MK-0646, 25.50; MK-0646+erlotinib, 15.0; 3 weeks of MK-0646 as single agent then combination of MK-0646 and erlotinib, 36.5. Median survivals of H1437-injected mice (days): control, 8.0; cisplatin, 21.0; MRK-003 (GSI), 30.0; GSI+cisplatin, 38.0; GSI+MK-0646, 42.0; erlotinib, 19.0; MK-0646, 26.0; MK-0646+erlotinib, 18.5; 3 weeks of MK-0646 as single agent then combination of MK-0646 and erlotinib, 35.0.